Tempus has built one of the largest libraries of clinical and molecular data in oncology, with over 30 million de-identified patient records spanning genomic, transcriptomic, proteomic, and clinical data. The platform's core offering is comprehensive genomic profiling: tumor and liquid biopsy sequencing that identifies actionable mutations, biomarkers (PD-L1, MSI-H, TMB), and molecular subtypes that guide treatment selection. What distinguishes Tempus from laboratory-only genomic services is the AI layer that sits on top of this data — algorithms that connect a patient's molecular profile to real-world outcomes from similar patients, published evidence, and available clinical trials.
Clinical trial matching is one of Tempus's most impactful features. According to the National Cancer Institute, only about 5% of adult cancer patients enroll in clinical trials, partly because matching eligible patients to appropriate studies is manual and time-consuming. Tempus's acquisition of Deep 6 AI in 2025 significantly expanded this capability, adding access to over 750 provider sites and 30 million patient records for trial matching. The combined platform has been shown to identify 25% more eligible patients and recruit up to 3 times faster than traditional methods.
Founded by Eric Lefkofsky in 2015 and headquartered in Chicago, Tempus went public (NASDAQ: TEM) in 2024. The platform partners with major academic medical centers and community oncology practices. Revenue comes from genomic testing, data licensing to pharmaceutical companies, and enterprise platform subscriptions.
This review evaluates Tempus exclusively for its oncology applications. As a specialized precision oncology platform rather than a general clinical decision support tool, it was not included in our overall CDS rankings. Within oncology, Tempus represents the leading AI-powered platform for molecularly guided treatment decisions and clinical trial matching.